Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,455 signal articles · 223 in last 24h · 132,911 total before filter · latest 1h ago
223last 24h
1156last 7d
203● bullish (7d)
123● bearish (7d)
208publishers
AllMacro280Earnings419M&A72Regulatory22Product10Analyst20
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Union Pacific (UNP) is Winning the Railroad Race. Can Norfolk Southern (NSC) Catch Up through the Merger?
Insider Monkey5d agoneutral
Union Pacific (UNP) is Winning the Railroad Race. Can Norfolk Southern (NSC) Catch Up through the Merger?

On July 27, Union Pacific Corporation (NYSE:UNP) and Norfolk Southern Corporation (NYSE:NSC) enhanced their joint merger application with expanded customer protections sent to the Surface Transportation Board (STB). Seeking to create the first single-line transcontinental network, the rails offered terms going beyond prior Class I combinations. They proposed doubling Committed Gateway Pricing eligibility to preserve […]

Solstice Stock Jumps After Calling Off a Major Acquisition
Barrons.com5d agobullish
Solstice Stock Jumps After Calling Off a Major Acquisition

Shares of Solstice Advanced Materials soared early Friday after the company called off a dramatic acquisition that would have turned the company into even more of an AI play. In early July, Solstice announced a cash and stock deal to buy Element Solutions Element makes products used in semiconductor manufacturing. Together, the companies would supply three legs of the AI value chain: The chips, the data centers, and the power that makes everything work.

INTU Q2 Deep Dive: AI Strategy and Customer Acquisition Take Center Stage
StockStory6d agoneutral
INTU Q2 Deep Dive: AI Strategy and Customer Acquisition Take Center Stage

Financial technology platform Intuit (NASDAQ:INTU) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 13.7% year on year to $4.35 billion. On the other hand, next quarter’s revenue guidance of $4.31 billion was less impressive, coming in 1.3% below analysts’ estimates. Its non-GAAP profit of $4.03 per share was 12.3% above analysts’ consensus estimates.

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?
Insider Monkey6d agobullish
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

Archer Aviation (ACHR) L A Live Vertiport News Puts Its Valuation Gap Back In Focus
Simply Wall St.6d agoneutral
Archer Aviation (ACHR) L A Live Vertiport News Puts Its Valuation Gap Back In Focus

Archer Aviation (ACHR) is back in focus after announcing a collaboration with Anschutz Entertainment Group to develop downtown Los Angeles’ first vertiport at L.A. LIVE, giving investors fresh information about its urban air taxi rollout. At a share price of $5.90, Archer Aviation has seen a 19.19% 1 month share price return but is still down 27.43% year to date, while the 1 year total shareholder return is down 35.52%. This points to recent momentum building off a weaker longer term base as...

KKR to Pay Record Settlement in Premerger-Filings Case
The Wall Street Journal6d agoneutral
KKR to Pay Record Settlement in Premerger-Filings Case

The amount KKR agreed to pay to settle a case with the Justice Department alleging that the private-equity giant withheld and altered documents in premerger filings. The previous record, a $12 million penalty, was collectively held by Edwards Lifesciences and Genesis MedTech. The DOJ said late yesterday that KKR failed to make complete and accurate filings for at least 16 deals in 2021 and 2022.